CellCarta

CellCarta is a global contract research organization (CRO) based in Montreal, Canada, specializing in precision medicine testing services. The company integrates expertise in immunology, histopathology, proteomics, and genomics to support drug development from discovery through late-stage clinical trials. Formed in 2019 from the merger of Caprion Biosciences and HistoGeneX, CellCarta has expanded through acquisitions, establishing a presence in Canada, the U.S., Belgium, Australia, and China. CellCarta offers a range of laboratory testing and biomarker analysis services, including immune monitoring, histopathology, proteomics, and genomics. The company also provides specimen logistics through CellCarta Logistics, ensuring global sample management and transportation. Its integrated biomarker testing solutions include custom assay development, digital pathology platforms, and multi-omics integration. CellCarta partners with biopharmaceutical companies to enhance drug development for targeted therapies, focusing on advancing personalized medicine by identifying biomarkers that predict patient responses to treatments.